Rosacea is a chronic inflammatory cutaneous disease of the convexities of the central face (cheeks, chin, nose and central forehead) and eyes with periorbital and perioral skin sparing. This condition is attributed to chronic vasodilation.
Remissions and exacerbations are common.
It typically begins after 30 years of age but may occur at any age. It commonly affects fair-skinned individuals.
The common presenting symptoms are facial flushing, stinging/burning erythema, telangiectasia, edema, papules, pustules, ocular lesions, and hypertrophy of the sebaceous glands of the nose with fibrosis (rhinophyma).
A history of episodic flushing often heralds onset of rosacea.
As the Hong Kong government launches a territory-wide coronavirus disease 2019 (COVID-19) vaccination programme, the Chinese University of Hong Kong (CUHK) and the University of Hong Kong (HKU) have shared findings of their independent telephone surveys gauging public views of the programme.
Treatment-naïve individuals with HIV continued to benefit from the dolutegravir-lamivudine regimen for nearly 3 years regardless of baseline disease characteristics and demographics, as shown by its noninferiority to dolutegravir plus tenofovir and emtricitabine observed in the subgroup analyses of the GEMINI trials presented at CROI 2021.
Sex appears to have a strong influence on many discrete pathways of inflammation that independently predict cardiovascular disease (CVD) and venous thromboembolism (VTE) events in patients with HIV on antiretroviral therapy (ART), according to a study presented at the Conference on Retroviruses and Opportunistic Infections 2021.